NCT05048017View on ClinicalTrials.gov

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions
Hepatocellular CarcinomaRegorafenibPD-1 Inhibitor
Interventions
DRUG

Regorafenib

Regorafenib, 120 mg, once a day, 3 weeks on/1 week off

DRUG

PD-1 inhibitor

"Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks."

Trial Locations (1)

100730

RECRUITING

Hai-Tao Zhao, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER